

### **Corporate & Admin Office:**

"Shilpa House", #12-6-214/A-1, Hyderabad Road, Raichur-584 135, Karnataka, India

Tel: +91-8532-238704, Fax: +91-8532-238876

Email: info@vbshilpa.com, Web: www.vbshilpa.com

CIN: L85110KA1987PLC008739

23 May 2022

To, Corporate Relationship Department, BSE Limited, 1st Floor, Rotunda Building, P.J. Towers, Dalal Street, Mumbai – 400 001. To,
National Stock Exchange of India
Limited,
Exchange Plaza, 5<sup>th</sup> Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E),
MUMBAI – 400 051.

Dear Sir/ Ma'am,

### Sub: Outcome of the Board Meeting

Ref: Regulation 30, 33 & 43 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Scrip Code: BSE - 530549/ Stock Symbol: NSE - SHILPAMED

With reference to the captioned subject we hereby wish to inform you that the Board at its meeting held today i.e., on 23 May 2022 has inter alia considered and approved the following:

### 1. Approval of Financial Statements

The audited financial results (Standalone and Consolidated) for the quarter and year ended 31 March 2022, pursuant to Regulation 33 (3) of Listing Regulations. The copy of the same including statement of assets and liabilities, statement of cash flows along with the Auditors' Report with unmodified opinion and a declaration to the effect that the Auditors have given unmodified opinion on the Audited financial result (Standalone and Consolidated) for the year ended 31 March 2022 (Please refer Annexure 1)

## 2. Recommendation of Dividend

Payment of dividend of Rs. 1.10/-(110%) per equity share of face value of Rs. 1/- each for the financial year 2021-2022, subject to approval of members in the ensuing Annual General Meeting.





### Corporate & Admin Office:

"Shilpa House", #12-6-214/A-1, Hyderabad Road, Raichur-584 135, Karnataka, India

Email: info@vbshilpa.com, Web: www.vbshilpa.com

Tel: +91-8532-238704, Fax: +91-8532-238876

CIN: L85110KA1987PLC008739

# 3. <u>Update on Slump sale of Active Pharmaceutical Ingredient Business (API) of the Company</u>

In furtherance to the Stock Exchange intimations dated 12 July 2021, 19 August 2021, 14 October 2021, 09 February 2022, 15 March 2022 and 02 April 2022 with regard to transfer of API business of the Company (the 'Transferor Company') on a slump sale basis as a going concern of Active Pharmaceutical Ingredient business of the Company to its wholly owned subsidiary Shilpa Pharma Lifesciences Limited (Formerly known as Shilpa Corporate Holdings Private Limited) bearing CIN U24100KA2020PLC134081 (the 'Transferee Company') by way of Business Transfer Agreement.

In this context, we hereby wish to inform you that the Company consequent to execution of Business Transfer agreement with Shilpa Pharma Lifesciences Limited (Formerly known as Shilpa Corporate Holdings Private Limited) dated 02 April 2022 is currently in the process of availing the requisite regulatory licenses from various authorities for the transfer.

# 4. Fund Raising plans in Shilpa Pharma Lifesciences Limited (A wholly owned subsidiary) by way of Initial Public offerings (IPO)

The Board has received a proposal from Shilpa Pharma Lifesciences Limited to consider fund raising for payment of Slump Sale consideration apart from financing its own working capital requirements & further expansion through an Initial Public Offer. Board has unanimously decided to let Shilpa Pharma Lifesciences Limited fund its sources through an Initial Public Offer including an option to provide an offer for sale by the Company. Board has requested them to file the DRHP and all related documents with SEBI for initiating the said offer.





### **Corporate & Admin Office:**

"Shilpa House", #12-6-214/A-1, Hyderabad Road, Raichur-584 135, Karnataka, India

Tel: +91-8532-238704, Fax: +91-8532-238876

Email: info@vbshilpa.com, Web: www.vbshilpa.com

CIN: L85110KA1987PLC008739

## 5. Appointment of Company Secretary & Compliance Officer

Pursuant to the provisions of Section 203 of the Companies Act, 2013 and the rules framed thereunder read with Regulation 6 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable regulations, the Board on the recommendation of Nomination & Remuneration Committee has approved the appointment of Ms. Ritu Tiwary, Member of Institute of Company Secretaries of India (Membership no A19046) as Company Secretary & Compliance officer who shall be a whole-time Key Managerial Personnel of the Company w.e.f 23 May 2022. (*Please refer Annexure 2*)

The Board meeting commenced at 11.30 A.M. and concluded at 04:15 P.M.

This is for your information and necessary records.

Thanking you.

For & on behalf of

Shilpa Medicare Limited

**Ritu Tiwary** 

**Company Secretary & Compliance Officer** 

**Enclosed:** 

Brief profile of Ms. Ritu Tiwary - Company Secretary & Compliance officer of the Company



### Corporate & Admin Office:

"Shilpa House", #12-6-214/A-1, Hyderabad Road, Raichur-584 135, Karnataka, India

Tel: +91-8532-238704, Fax: +91-8532-238876

Email: info@vbshilpa.com, Web: www.vbshilpa.com

CIN: L85110KA1987PLC008739

In view of the above and in pursuance to the requirements of Regulation 30 of (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular CIR/CFD/CMD/4/2015 dated 09 September 2015 following the information is given below:

Sub: Brief profile of Ms. Ritu Tiwary - Company Secretary & Compliance officer of the Company

Name of the Company Secretary & Compliance Officer	Ms. Ritu Tiwary
Effective Date of Appointment	23 May 2022
Terms of Appointment	Appointed as Company Secretary & Compliance officer of the Company
Brief Profile	Ms. Ritu Tiwary, aged 45 years is a qualified Company Secretary with Post-Graduation in Commerce and Bachelor of Law. She has over 2 decades of experience in Company Secretarial, Compliance and Governance management.
	Ms. Ritu has throughout been associated with listed company and has handled various assignments viz., Corporate debt restructuring, scheme of arrangement, listing, delisting, preferential issue, dealt with Service Tax handling reverse charge mechanism, actively engaged in availing various subsidies for establishment of new solar power plant in the State for group companies etc., apart from the regular corporate secretarial functions.
	In her previous employment as GM- CS & Legal she was heading the Regulatory Compliance, Compliance management, Intellectual Property, Litigation and in charge of Contract Management. She has represented the Company at various judicial forums. Her last employment was at Bambino Agro Industries Limited.
Disclosure of relationships between directors	Ms. Ritu Tiwary is not related to any Director or Key Managerial Person of the Company.

